Biotech closes on $9M for stem cell, cord blood research

09/14/2007 | American City Business Journals

Aldagen has raised $9 million in funding to use for its research with stem cells derived from bone marrow, blood and umbilical cords. The biotech company currently has three drugs trials under way for improving safety in cord blood transfusions and treating advanced heart failure and blocked extremities.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL